Lee Nami, Park So Jeong, Kang Dongwoo, Jeon Ja Young, Kim Hae Jin, Kim Dae Jung, Lee Kwan-Woo, Boyko Edward J, Han Seung Jin
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea.
Data Science Team, Hanmi Pharmaceutical Co., Ltd, Seoul, South Korea.
Diabetes Care. 2022 May 1;45(5):1141-1150. doi: 10.2337/dc21-1659.
The natural course of diabetes of the exocrine pancreas (DEP) is not well established. We aimed to compare the risk of insulin initiation, diabetic complications, and mortality between DEP and type 2 diabetes.
Using the Korean National Health Insurance Service-Health Screening Cohort between 2012 and 2017, we divided patients with diabetes into those with diabetes without prior pancreatic disease (indicated type 2 diabetes, n = 153,894) and diabetes with a prior diagnosis of pancreatic disease (indicated DEP, n = 3,629). ICD-10 codes and pharmacy prescription information were used to define type 2 diabetes, DEP, and acute and chronic diabetes complications. Kaplan-Meier curves were produced to compare insulin use over time between groups. We created logistic regression models for odds of progression to diabetic complications and mortality.
DEP was associated with a higher risk of insulin use than type 2 diabetes (adjusted hazard ratio 1.38 at 5 years [95% CI 1.30-1.47], P < 0.0001). Individuals with DEP showed higher risks of hypoglycemia (odds ratio 1.85 [1.54-2.21], P < 0.0001), diabetic neuropathy (1.38 [1.28-1.49], P < 0.0001), nephropathy (1.38 [1.27-1.50], P < 0.0001), retinopathy (1.10 [1.01-1.20], P = 0.0347), coronary heart disease (1.59 [1.48-1.70], P < 0.0001), cerebrovascular disease (1.38 [1.28-1.49], P < 0.0001), and peripheral arterial disease (1.34 [1.25-1.44], P < 0.0001). All-cause mortality was higher in those with DEP (1.74 [1.57-1.93], P < 0.0001) than in those with type 2 diabetes.
DEP is more likely to require insulin therapy than type 2 diabetes. Hypoglycemia, micro- and macrovascular complications, and all-cause mortality events are higher in DEP compared with type 2 diabetes.
外分泌胰腺糖尿病(DEP)的自然病程尚未明确。我们旨在比较DEP与2型糖尿病患者起始使用胰岛素的风险、糖尿病并发症及死亡率。
利用2012年至2017年韩国国民健康保险服务健康筛查队列,我们将糖尿病患者分为既往无胰腺疾病的糖尿病患者(即2型糖尿病,n = 153,894)和既往诊断为胰腺疾病的糖尿病患者(即DEP,n = 3,629)。使用国际疾病分类第十版(ICD - 10)编码和药房处方信息来定义2型糖尿病、DEP以及急慢性糖尿病并发症。绘制Kaplan - Meier曲线以比较两组随时间使用胰岛素的情况。我们建立逻辑回归模型来分析发生糖尿病并发症和死亡的几率。
与2型糖尿病相比,DEP起始使用胰岛素的风险更高(5年时调整后风险比为1.38 [95%置信区间1.30 - 1.47],P < 0.0001)。DEP患者发生低血糖的风险更高(比值比1.85 [1.54 - 2.21],P < 0.0001)、糖尿病神经病变(1.38 [1.28 - 1.49],P < 0.0001)、肾病(1.38 [1.27 - 1.50],P < 0.0001)、视网膜病变(1.10 [1.01 - 1.20],P = 0.0347)、冠心病(1.59 [1.48 - 1.70],P < 0.0001)、脑血管疾病(1.38 [1.28 - 1.49],P < 0.0001)和外周动脉疾病(1.34 [1.25 - 1.44],P < 0.0001)。DEP患者的全因死亡率高于2型糖尿病患者(1.74 [1.57 - 1.93],P < 0.0001)。
与2型糖尿病相比,DEP更有可能需要胰岛素治疗。与2型糖尿病相比,DEP发生低血糖、微血管和大血管并发症以及全因死亡事件的风险更高。